The therapeutic resources currently available for AD include cholinesterase inhibitors (donepezil, rivastigmine, and galantamine), N-methyl-D-aspartate (NMDA) receptor antagonists (memantine), chelating agents (deferiprone), and metal–protein attenuating compounds (MPACs) (clioquinol) [1]. This evidence concerns the gene BCHE and Alzheimer disease.